Main Street Group’s Ensysce Biosciences ENSC Stock Holding History

Main Street Group’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$185	–	812
2024 Q2	$185	Hold	25	–	–	﹤0.01%	833
2024 Q1	$289	Buy	+25	New	+$397	﹤0.01%	860

Other funds holding ENSC

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Main Street Group's ENSC Position: Q3 2024 in Review

Main Street Group sold out of Ensysce Biosciences (ENSC) in Q3 2024, closing a stake of 25 shares — an estimated $185 sold.

Main Street Group first reported a position in ENSC in Q1 2024 and held it in 2 quarters. The position peaked at $289 in Q1 2024. 12 funds tracked by Wall St. Rank hold ENSC as of Q3 2024.

Main Street Group reported no remaining Ensysce Biosciences position as of Q3 2024 after selling out during the quarter.
Main Street Group sold 25 Ensysce Biosciences shares in Q3 2024, an estimated $185.
Main Street Group first reported a position in Ensysce Biosciences in Q1 2024 and held it in 2 quarters.
Main Street Group's Ensysce Biosciences position peaked at $289 in Q1 2024.
12 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2024.

Based on Main Street Group's 13F filing for Q3 2024, filed 13 Nov 2024.